DNA sequencing is the read step that the “Imperium” pitch builds everything else on. Before you can design a genetic sequence or write it into existence, you have to be able to read the code in the first place, and that reading has gotten so cheap and fast that the whole downstream opportunity opened up. This article explains the read layer, names the leaders, and shows how it anchors the thesis.
The Read Layer of the Stack
The pitch organizes the DNA economy into three steps. Sequencing reads the code, decoding the order of bases in a strand of DNA. Synthesis writes it, building new strands from scratch. Programming, the layer Ginkgo Bioworks occupies, runs it, turning those written sequences into working biological processes.
Sequencing is the foundation because everything else depends on knowing what the code says. You cannot write a correction until you have read the original, and you cannot program a cell until you know what is already there. That is why the read layer matured first, and why its cost decline is the quiet engine behind the whole story.
Short Reads, Long Reads, and Single Cells
The technology splits into three complementary tools. Short-read sequencing breaks DNA into tiny fragments, reads them in parallel, and reassembles the result, which is fast and cheap but can miss long, repetitive stretches. Long-read sequencing reads much longer pieces at once, catching what short reads miss at a higher cost per read.
Then there is single-cell work, a different axis entirely, that reads the DNA or RNA of one cell at a time rather than averaging millions of cells together. That matters for understanding how individual cells differ inside a tissue, which is central to cancer and immunology research. Each of the three tools answers a different question, which is why the market supports multiple leaders rather than one.
The Leaders and Their Roles
Three companies anchor the read layer. Illumina (ILMN) dominates short-read sequencing, the workhorse of clinical and research genomics, with the installed base and scale that come with being the default choice. Pacific Biosciences (PACB) leads in long reads, the approach that handles the difficult regions short reads fumble. And 10x Genomics (TXG) leads in single-cell profiling, the layer that reads individual cells rather than bulk samples.
The three are complements, not pure competitors, and a well-equipped genomics lab often runs all three for different questions. The pitch itself treats the read layer as a neighbor rather than a pick, and for good reason: it is a mature, increasingly commodity-like business. Our Illumina stock piece and next-generation sequencing explainer cover the leaders and the technology in more depth.
The Falling Cost and Its Consequences
The read layer’s defining fact is the price of a genome. Reading a human genome cost millions of dollars and took years at the turn of the century. Today it costs a few hundred dollars and takes about a day. That collapse is the factual core of the pitch’s claim that DNA is “fast enough, cheap enough, and scalable enough” to matter.
The consequence cuts both ways. Cheap reading is what unlocked the whole field, but it also means the read layer no longer commands the premium pricing it once did. The margin, and the pitch’s attention, have shifted downstream to the write layer, which is where Twist Bioscience, the pitch’s silicon-layer pick, operates. Twist is also a customer and partner of Illumina, so the read and write layers are commercially tied together, not siloed.
How the Read Layer Feeds the Imperium Thesis
In the pitch’s framing, reading DNA is the on-ramp to the real opportunity. Cheap reads make design and writing practical, and practical writing is what turns biology into a software problem. The sequencing names are therefore the supporting cast: essential, established, and largely priced as such, while the pitch’s picks sit in the earlier, faster-moving write layer.
For an investor, the takeaway is to understand the read layer as context. It is real, it is cheap, and it is why the thesis is even possible. The more speculative, higher-ceiling opportunity the pitch is selling lives one step over, in synthesis. Our Twist Bioscience stock piece picks up exactly where the read layer leaves off.
The Read Layer’s Next Act
The read layer is entering a new phase, one defined less by falling cost and more by growing reach. Sequencing has spread from research labs into the clinic, into population screening, and into recurring applications like cancer monitoring, where a patient is tested repeatedly over time rather than once. Those recurring-use markets are larger than the research market that built the leaders, and they reward whoever pairs accuracy with the lowest cost per sample.
The pitch is right to treat the read layer as context rather than the main event. Reading DNA is a settled, increasingly commodity business, and the more exciting economics have moved one step over to the write layer, where the cost curve is still bending and the field is still sorting out its winners. For an investor, the read layer is the foundation, not the ceiling.
Ready to see the research? Click here to access Adam O’Dell’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.